Literature DB >> 10634347

Global measles control and regional elimination, 1998-1999.

.   

Abstract

In 1989, the World Health Assembly adopted the goal of reducing measles morbidity and mortality by 90% and 95%, respectively, by 1995, compared with estimates of the disease burden in the prevaccine era. In 1990, the World Summit for Children adopted a goal of vaccinating 90% of children against measles by 2000. Three regions of the World Health Organization (WHO) have targeted elimination: in 1994, the American Region (AMR) targeted elimination by 2000; in 1997, the Eastern Mediterranean Region (EMR) targeted elimination by 2010; and in 1998, the European Region (EUR) targeted elimination by 2007. This report updates progress since 1997 toward global measles control and regional elimination of measles, and includes vaccination coverage and disease surveillance data received by WHO as of August 14, 1999. Data for 1998 suggest that routine measles vaccination coverage has declined in some regions, the number of countries reporting cases and coverage to WHO has decreased, and measles continues to be an important cause of morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10634347

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  11 in total

1.  Measles related complications and the role of vitamin A supplementation.

Authors:  Ashok Mishra; Subodh Mishra; Pankaj Jain; Rahul Singh Bhadoriya; Rakesh Mishra; Chandrakant Lahariya
Journal:  Indian J Pediatr       Date:  2008-06-21       Impact factor: 1.967

2.  Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors.

Authors:  H Tatsuo; N Ono; Y Yanagi
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Simultaneous detection of measles virus, rubella virus, and parvovirus B19 by using multiplex PCR.

Authors:  María del Mar Mosquera; Fernando de Ory; Mónica Moreno; Juan E Echevarría
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

4.  Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor.

Authors:  N Ono; H Tatsuo; Y Hidaka; T Aoki; H Minagawa; Y Yanagi
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Fully vaccinated children are rare: immunization coverage and seroprevalence in Austrian school children.

Authors:  Markus Ringler; Georg Göbel; Johannes Möst; Kurt Weithaler
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

6.  Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles.

Authors:  Judith J Ryon; William J Moss; Mwaka Monze; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

7.  Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants.

Authors:  Hayley A Gans; Linda L Yasukawa; Cathryn Z Zhang; Rima Hanna Wakim; Mary Rinki; Ross Dehovitz; Ann M Arvin
Journal:  Viral Immunol       Date:  2008-06       Impact factor: 2.257

8.  Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys.

Authors:  Sallie R Permar; Sherry A Klumpp; Keith G Mansfield; Woong-Ki Kim; Darci A Gorgone; Michelle A Lifton; Kenneth C Williams; Jörn E Schmitz; Keith A Reimann; Michael K Axthelm; Fernando P Polack; Diane E Griffin; Norman L Letvin
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Mass measles rubella immunization campaign: bhutan experience.

Authors:  Bhakta R Giri; Pem Namgyal; Kp Tshering; Kp Sharma; Tandin Dorji; Chewang Tamang
Journal:  Indian J Community Med       Date:  2011-04

10.  Practical observations from an epidemiological investigation of a measles outbreak in a district of India.

Authors:  Ashok Mishra; Subodh Mishra; Chandrakant Lahariya; Pankaj Jain; Rahul S Bhadoriya; Dhiraj Shrivastav; Neera Marathe
Journal:  Indian J Community Med       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.